Sort
21,453 grants matching “tuberculosis”
DRUG TARGETING M. TUBERCULOSIS ARABINOSYL TRANSFERASES
$156,853University Of Tennessee Health Sci Ctr · K22 · FY2000 · AI
Administrative Supplement to GM102864, Funds for a Fluorimeter
$156,843Peter J Tonge · State University New York Stony Brook · R01 · FY2018 · GM
Administrative Core
$156,784David Branch Moody · Brigham And Women'S Hospital · U19 · FY2022 · AI
TUBERCULOSIS PREVENTION, CONTROL/ELIMINATION, LABORATORY, AND HUMAN RESOURCES DEV
$156,765Tai Leigh Wright · Wyoming State Department Of Health · U52 · FY2014 · PS
DEVELOPMENT OF IMMUNE EVASION IN TUBERCULOSIS
$156,753University Of California San Francisco · P01 · FY2000 · AI
Impact of Effective Chemotherapy on Transmission of Drug Resistant Tuberculosis
$156,573Anton Carel Stoltz · University Of Pretoria · R01 · FY2016 · AI
Developing Intravesical Liposomes for Interstitial Cystitis
$156,564Jonathan H Kaufman · Lipella Pharmaceuticals, Inc. · R42 · FY2009 · DK
Optimizing mHealth for adherence monitoring and intervention
$156,511Jessica Elizabeth Haberer · Massachusetts General Hospital · K24 · FY2019 · MH
Impact of TB on Outcome of HIV in Pregnant Women
$156,368Richard E Chaisson · Johns Hopkins University · R01 · FY2012 · HD
Animal Model Core E
$156,346Clare Margaret Smith · Brigham And Women'S Hospital · U19 · FY2021 · AI
Virulence factors of clinical MTB strains with enhanced growth in macrophages
$156,107Kathleen Davis Eisenach · Univ Of Arkansas For Med Scis · R21 · FY2009 · AI
Improved Tools for Nontuberculous Mycobacteria Lung Disease
$156,089Keira Alexis Cohen · Johns Hopkins University · K08 · FY2019 · HL
COENZYME F420 BIOSYNTHESIS IN MYCOBACTERIUM
$156,054University Of Iowa · R01 · FY2000 · GM
Novel inhibitors of M. tuberculosis RNA Polymerase
$156,000Cumbre, Inc. · R43 · FY2003 · AI
Efficacy of combination therapy in the Cynomolgus macaque model
$155,965Joanne L. Flynn · University Of Florida · P01 · FY2017 · AI
Directly observed antiretroviral therapy in drug abusers
$155,869Johns Hopkins University · K23 · FY2004 · DA
INFECTIOUS DISEASES CORE
$155,792David C Perlman · New York University · P30 · FY2012 · DA
Nicotine in HIV-1 and Mycobacterium tuberculosis Neuropathogenesis
$155,768Robert Bryan Rock · University Of Minnesota · K08 · FY2007 · DA
ACTG365--STEADY STATE PK INTERACTION STUDY OF INDINAVIR &RIFABUTIN
$155,764University Of Southern California · M01 · FY2001 · RR
ACTG365--STEADY STATE PK INTERACTION STUDY OF INDINAVIR &RIFABUTIN
$155,764University Of Southern California · M01 · FY2000 · RR
PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PERSONS
$155,764University Of Southern California · M01 · FY2001 · RR
RIFAPENTINE CLINICAL TRIAL--RISK FACTORS FOR RELAPSE AMONG HIV+ PTS
$155,764University Of Southern California · M01 · FY2001 · RR
URINARY CYTOKINES AS MARKERS FOR RESPONSE TO TB THERAPY
$155,764University Of Southern California · M01 · FY2001 · RR
Identifying Men's Preferences for a Male-Centered TB Care Intervention
$155,649Andrew Medina-Marino · Foundation For Professional Development · R21 · FY2021 · AI
Molecular mechanisms used by Chlamydia trachomatis to manipulate membrane fusion
$155,583Fabienne Michelle Paumet · Thomas Jefferson University · R01 · FY2015 · AI